Idhifa OverviewEnasidenib (INN; trade name Idhifa) is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. Contents 1 Medical use 2 Adverse effects 3 Pharmacology 4 History 5 References Medical use Enaside...
Read more Idhifa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Enasidenib
Recent Idhifa Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 100mg, 50mg
NDC Database Records for Idhifa: (2 results)Sorted by National Drug Code
- 59572-705 Idhifa 50 mg Oral Tablet, Film Coated by Celgene Corporation
- 59572-710 Idhifa 100 mg Oral Tablet, Film Coated by Celgene Corporation